78 related articles for article (PubMed ID: 8904046)
1. Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
Ayisi NK
East Afr Med J; 1995 Oct; 72(10):654-7. PubMed ID: 8904046
[TBL] [Abstract][Full Text] [Related]
2. Modified tetrazolium-based colorimetric method for determining the activities of anti-HIV compounds.
Ayisi NK; Gupta SV; Qualtiere LF
J Virol Methods; 1991 Aug; 33(3):335-44. PubMed ID: 1664434
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV.
Parkin NT; Schapiro JM
Antivir Ther; 2004 Feb; 9(1):3-12. PubMed ID: 15040531
[TBL] [Abstract][Full Text] [Related]
4. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
Malley SD; Grange JM; Hamedi-Sangsari F; Vila JR
Lancet; 1994 May; 343(8908):1292. PubMed ID: 7910296
[No Abstract] [Full Text] [Related]
5. Novel alkaloids from the tropical plant Ancistrocladus abbreviatus inhibit cell killing by HIV-1 and HIV-2.
Manfredi KP; Blunt JW; Cardellina JH; McMahon JB; Pannell LL; Cragg GM; Boyd MR
J Med Chem; 1991 Dec; 34(12):3402-5. PubMed ID: 1766007
[No Abstract] [Full Text] [Related]
6. In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.
Winslow DL; Mayers D; Scarnati H; Lane J; Bincsik A; Otto MJ
AIDS; 1994 Jun; 8(6):753-6. PubMed ID: 8086132
[TBL] [Abstract][Full Text] [Related]
7. What we know about anti-HIV drugs.
Treat Rev; 1995 May; (no 18):3-4. PubMed ID: 11362592
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
9. HIV genetic diversity: any implications for drug resistance?
Jülg B; Goebel FD
Infection; 2005 Aug; 33(4):299-301. PubMed ID: 16091906
[TBL] [Abstract][Full Text] [Related]
10. Unusual single-stranded polyribonucleotides as potent anti-HIV agents.
Broom AD; Agrawal VK; Tutonda MG; Fain HD; Buckheit RW
J Med Chem; 1995 Aug; 38(17):3253-7. PubMed ID: 7650678
[TBL] [Abstract][Full Text] [Related]
11. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
Balzarini J; Pannecouque C; De Clercq E; Pavlov AY; Printsevskaya SS; Miroshnikova OV; Reznikova MI; Preobrazhenskaya MN
J Med Chem; 2003 Jun; 46(13):2755-64. PubMed ID: 12801238
[TBL] [Abstract][Full Text] [Related]
14. Zalcitabine and didanosine.
Lipsky JJ
Lancet; 1993 Jan; 341(8836):30-2. PubMed ID: 8093278
[No Abstract] [Full Text] [Related]
15. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
[TBL] [Abstract][Full Text] [Related]
16. Short, terminally phosphorylated oligoriboguanylic acids effectively inhibit cytopathicity caused by human immunodeficiency virus.
Fujihashi T; Sakata T; Kaji A; Kaji H
Biochem Biophys Res Commun; 1994 Sep; 203(2):1244-50. PubMed ID: 7916572
[TBL] [Abstract][Full Text] [Related]
17. Effects of serotonin and melanin on in vitro HIV-1 infection.
Sidibe S; Saal F; Rhodes-Feuillette A; Lagaye S; Pelicano L; Canivet M; Peries J; Dianoux L
J Biol Regul Homeost Agents; 1996; 10(1):19-24. PubMed ID: 9049777
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)-2-substituted-5,6-dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole.
Porcari AR; Devivar RV; Kucera LS; Drach JC; Townsend LB
J Med Chem; 1998 Apr; 41(8):1252-62. PubMed ID: 9548815
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 group O sensitivity to antiretroviral drugs.
Descamps D; Collin G; Loussert-Ajaka I; Saragosti S; Simon F; Brun-Vézinet F
AIDS; 1995 Aug; 9(8):977-8. PubMed ID: 7576340
[No Abstract] [Full Text] [Related]
20. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
